Interim report
Page 1
Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 INDGN/SE/2026-27/63 29 October 2026 BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051, India. Trading symbol: INDGN Dear Sir / Madam, Subject: Outcome of Board Meeting held on October 29, 2026 Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we hereby inform you that the Board of Directors of Indegene Limited at its meeting held on Thursday, October 29, 2026, has, inter alia: 1. Approved unaudited Standalone and Consolidated Financial Re sults along with Limited Review Report of the Auditors thereon for the 2nd quarter and half year ended September 30, 2026. The Financial Results along with the Limited Review Report of the Auditors with an unmodified opinion and CFO declaration are enclosed herewith as Annexure – A. 2. Approved allotment under RSU Scheme 2020 and ESOP Scheme 2020. The detailed particulars required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in Annexure - B. 3. Noted and accepted the resignation tendered by Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive - Non-Independent Director of the Company, with effect from close of business hours of October 29, 2026. The Board placed on record its appreciation for the valuable guidance, support and services rendered by Mr. Mark Francis Dzialga during his association with the Company. A copy of the resignation letter is enclosed herewith as Annexure - C. 4. Noted the re-constitution of the Nomination and Remuneration Committee and Investment Committee consequent to the cessation of membership of Mr. Mark Francis Dzialga from both the Committees. The composition of the reconstituted committees is provided in Annexure – D. 5. Noted and accepted the resignation tendered by Ms. Srishti Ramesh Kaushik (M. No.: A21609) on October 29, 2026, from the position of Company Secretary, Compliance Officer and Key Managerial Personnel of the Company. The Board placed on record its appreciation for the services and contributions rendered by Ms. Srishti Ramesh Kaushik during her tenure as Company Secretary of the Company and will be relieved from her duties with effect from the close of business hours on December 02, 2026. A copy of the resignation letter is enclosed herewith as Annexure – E. The detailed particulars required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025 -CFD-POD2/I/3762/2026 dated January 30, 2026, are provided in Annexure - F.
Page 2
2 6. Approved amendment to the Prevention of Sexual Harassment Policy of the Company. Please be informed that pursuant to the SEBI (Prohibition of Insider Trading) Regulations 2015 and the Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the Trading Window for dealing in the securities of the Company by its Designated Pers ons shall reopen with effect from Monday, 02nd November, 2026. The meeting of the Board of Directors commenced at 06:30 PM (IST) and concluded at 07:16 PM (IST). The above information will be made available on the website of the Company: https://www.indegene.com/ We request you to kindly take the same on record. Thanking You Yours Sincerely, For Indegene Limited Srishti Ramesh Kaushik Company Secretary and Compliance Officer Encl: A/a
Page 3
Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds, Bengaluru – 560 001 Karnataka, India Tel: +91 (80) 6188 6000 Fax: +91 (80) 6188 6011 INDEPE NDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM CONSOLIDATED FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of INDEGENE LIMITED (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”), for the quarter and six months ended September 30, 2026 (“the Statement”) being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requir ements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, ha s been prepared in accordance with the recognition an d measurement principles laid do wn in the Indian Accounting St andard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Revi ew Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” , issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of Parent’s personnel responsible for financia l and accounting matters, and applying analytical and ot her review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. The Statement includes the results of the entities as mentioned in Annexure I to this review report. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the inform ation required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement. Page 1 of 3 Annexure A
Page 4
Page 2 of 3 6. The c onsolidated unaudited financial results in cludes the interim financial information of 1 su bsidiary and 10 step down subsidiaries which have not been reviewed by their auditors, whose inte rim financial information reflects total assets of Rs 906 million as at September 30 2026, total revenue of Rs. 385 million and Rs 798 million for the quarter and six months ended September 30, 2026 respectively, total loss after tax of Rs. 47 million and Rs. 59 million for the q uarter and six months ended September 30, 2026 respectively, and other comprehensive income/(loss) of Rs. 17 million and Rs. (1) million for the quarter and six months ende d S eptember 30, 2026 respectively, as considered in the Statement. According to the information and explanations given to us by the Management, these interi m financial information are no t ma terial to the Group. Our Conclusion on the Statement is not modified in respect of our reliance on the interim financial information certified by the Manage ment. For Deloitte Haskins & Sells Chartered Accountants Firm’s Registration No. 008072S Sathya P Koushik Partner Membership No.: 206920 UDIN: 26206920ICUBWH7892 Place: Bengaluru Date: October 29, 2026
Page 5
Page 3 of 3 Annexure I to Independent Auditor’s Review Report on Review of Interim Consolidated Financial Results. The Consolidated Unaudited Financial Results for the quarter and six months ended September 30, 2026 include financial results of the following companies: Sr. No. Company Name Category Country of Incorporation 1 Indegene Limited Parent Company India 2 ILSL Holdings Inc. Wholly Owned Subsidiary USA 3 Indegene Inc. Step Down Subsidiary USA 4 Indegene Healthcare Canada Inc. Step Down Subsidiary Canada 5 DT Associates Research and Consulting Services Ltd Step Down Subsidiary England 6 DT Associates Research and Consulting Inc. Step Down Subsidiary USA 7 Cult Health LLC Step Down Subsidiary USA 8 Indegene Japan LLC Step Down Subsidiary Japan 9 Indegene Healthcare Mexico S DE RL DE CV Wholly Owned Subsidiary Mexico 10 Indegene Ireland Limited Wholly Owned Subsidiary Ireland 11 Indegene Healthcare Germany GmbH (Trilogy Writing & Consulting GmbH and Indegene Healthcare Germany GmbH merged vide agreement dated July 22, 2026 merger effective April 1, 2026) Step Down Subsidiary Germany 12 Indegene Fareast Pte Ltd Step Down Subsidiary Singapore 13 Indegene Europe LLC Step Down Subsidiary Switzerland 14 Indegene Lifesystems Consulting (Shanghai) Co. Ltd. Step Down Subsidiary China 15 Indegene Healthcare UK Limite d Step Down Subsidiary England 16 Trilogy Writing & Consulting Limited Step Down Subsidiary England 17 Trilogy Writing & Consulting Inc. Step Down Subsidiary USA 18 Indegene Spain S.L.U Step Down Subsidiary Spain 19 MJL Communications Group Ltd Step Down Subsidiary England 20 MJL Advertising Limited Step Down Subsidiary England 21 BioPharm Parent Holding, Inc Step Down Subsidiary USA 22 BioPharm Communications LLC Step Down Subsidiary USA 23 Addressable Health LLC Step Down Subsidiary USA 24 Warn and Co Limited Step Down Subsidiary England 25 Cake Kommunikations Holding GmbH Step Down Subsidiary Austria 26 Cake Kommunikations GmbH (AT) Step Down Subsidiary Austria 27 CAKE Kommunikations AG Step Down Subsidiary Switzerland 28 Cake Kommunikations GmbH (DE) Step Down Subsidiary Germany
Page 6
INDEGENE LIMITED CIN No. L 73100KA1998PLC102040 Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2026 (All amounts in ~ millions, exceot share data and where otherwise stated) SI.No. Particulars Quarter ended Six months ended Year ended 30 Septem her 30June 30 September 30 September 30 Septem her 31 March 2026 2026 2025 2026 2025 2026 Unaudited Unaudited Unaudited Unaudited Unaudited Audited I Income (a) Revenue from operations 11 ,223 10,631 8,042 21,854 15,650 35,105 (b) Other income (net) 150 290 197 440 418 720 Total income 11,373 10,921 8,239 22,294 16,068 3S,825 2 Expenses (a) Employee benefits expense 6,817 6,591 5,158 13,408 9,973 21 ,977 (b) Finance costs 69 64 38 133 75 193 ( c) Depreciation and amortisation expense 464 441 234 905 450 1,264 (d) Other expenses 2,549 2,298 1,478 4,847 2,718 6,938 Total expenses 9,899 9,394 6,908 19,293 13,216 30,372 3 Profit before exceptional item and tax (1-2) 1,474 1,S27 1,331 3,001 2,8S2 S,4S3 4 Exceptional items (net) - - - (203) 5 Profit before tax (3+4) 1,474 1,527 1,331 3,001 2,8S2 5,250 6 Tax expense - Current tax 411 293 379 ' 704 663 1,763 - Deferred tax (60' 72 (69) 12 4 (524) Total tax expenae 351 365 310 716 667 1,239 7 Profit for the period/year (5-6) 1,123 1,162 1,021 2,285 2,185 4,011 8 Other Comprehenaive Income (OCI), net oftaxe1 Items that will not be reclassified subsequently to the statement of profit or loss: Remeasurement of defined benefit obligat ion 52 (29) 24 23 36 41 Deferred tax relating to items that will not be reclassified to profit and loss (13) 7 (6) (6) (9) (10) Items that will be reclas,if15 subsequently to proftJ or loss: Exchange differences on translating the financial statements of foreign operations 218 97 466 315 624 1,412 Net change in fair value of forward contracts designated as cash flow hedges (63) 58 (5) - (66) Deferred tax relating to items that will be classified to profit and loss 16 05' I 17 Total Other Comprehensive Income for the period/year (net of tax) 210 118 484 328 651 1,394 9 Total Comprehen1ive Income for the period/year (7+8) 1,333 1,280 1,505 2,613 2,836 5,405 Profit for the period/year attributable to: Owners of the Parent 1,123 1,162 1,021 2,285 2,185 4,011 Other Comprehensive Income for the period/year attributable to: Owners of the Parent 210 118 484 328 651 1,394 Total Comprehensive Income for the period/year attributable to Owners of the Parent 1,333 1,280 1,505 2,613 2,836 5,405 10 Paid-up equity share capital (Face value oft 2 each) 481 481 480 481 480 481 II Other eouitv 30 906 12 Earnings per equity 1hare (face value oft 2 each)* (a) Basic (int) 4.67 4.84 4.26 9.50 9.12 16.72 (b) Diluted (in ,i 4.64 4.81 4.23 9.44 9.05 16.62 *Earnings per share is not annualised for quarter aod six months ended. See accompanying no/es lo the Consolidated Financial Results
Page 7
INDEGENE LIMITED CIN No. L73IO0KA1998PLCI02040 Statement of Consolidated Assets and Liabilities (All amounts in~ millions) As at As at Particulars 30 September 2026 Ji March 2026 Unaudited Audited A ASSETS I Non-current assets (a) Property, plant and equipment 809 586 (b) Capital work-in-progress - 118 ( c) Right-of-use assets 1,476 1,354 (d) Goodwill 11,609 11,343 ( e) Other intangible assets 4,404 4,833 (f) Financial assets (i) Other financial assets 227 804 (g) Deferred tax assets (net) 763 768 (h) Non-current tax assets (net) 37 172 (i) Other non-current assets 34 41 Total non current assets 19,359 20,019 II Current assets (a) Financial assets ( i) Investments 10,191 10,995 ( ii) Trade receivables Billed 7,982 7,702 Unbilled 3,468 2,116 ( iii) Cash and cash equivalents 1,414 3,008 (iv) Other bank balances 955 811 (v) Other financial assets 1,483 103 (b) Current tax assets (net) 709 65 ( c) Other current assets 1,372 1,384 Total current assets 27,574 26,184 Total assets 46,933 46,203 B EQUITY AND LlABILITIES 1 Equity (a) Equity share capital 481 481 (b) Other equity 33,103 30,906 Total equity 33,584 31,387 2 Liabilities I Non-current liabilities (a) Financials liabilities ( i) Lease liabilities 1,156 1,050 (ii) Other financial liabilities 102 2,031 (b) Provisions 913 873 Total non-current liabilities 2,171 3,954 II Current liabilities (a) Financials liabilities (i) Lease liabilities • 417 394 (ii) Trade payables Total outstanding dues of micro enterprises and small enterprises and 54 26 Total outstanding dues of creditors other than micro enterprises and small enterprises 1,947 1,781 ( iii) Other financial liabilities 4,253 3,055 (b) Other current liabilities 3,413 4,325 ( c) Provisions 903 798 (d) Current tax liabilities (net) 191 483 Total current liabilities 11,178 10,862 Total liabilities 13,349 14,816 Total equity and liabilities 46,933 46,203 Stt Ott:Olftlpanymg notes to the Consohdated Fmanc,al Results
Page 8
INDEGENE LIMITED CIN No. L73100KA1998PLC102040 Statement of Consolidated Cash Flow Particulars A. Cash flows from operating activities Profit before tax for the period Adjustments to reconcile profit for the period to net cash generated from operating activities: Depreciation and amortisation expense Finance costs Interest income and dividend income Net gain on disposal / fair valuation of investments Gain on termination oflease Gain on sale of fixed assets Bad debts written off Expected credit loss provision on trade receivables and advances Equity settled share based payment expense Effect of exchange gain on restatement Operating profit before working capital changes Movements in working capital: Increase in trade receivables Decrease in loans and advances and other assets Increase in liabilities Increase in provisions Cash generated from operating activities Income tax paid (net) Net cash generated/ (used) from operating activities (A) B. Cash flows from investing activities Purchase of property, plant and equipment Interest received Payment of contingent consideration pertaining to acquisition of business Amount transferred to Escrow agent for acquisition Purchase of Investments accounted for using the FVTPL Redemption oflnvestrnents Investment in fixed deposit Redemption / maturity of fixed deposit Net cash generated/ (used )in investing activities (B) C. Cash flows from financing activities Proceeds from fresh issue of equity shares (net of share issue expense) Interest and finance charges paid Payment of lease liabilities Dividend Paid Net cash used in from f"mancing activities ( C) Net increHe / (decrease) in cash and c85h equivalents (A+B+C) Cash and cash equivalents at the beginning of the period Effect of exchange differences on translation of foreign currency cash and cash equivalents Cash and cash equivalents at the end of the period For the purpose of the statement of cash flow, cash and cash equivalents comprise the following: Particulars Balances with banks: • In current accounts - In deposit accounts Total See accompanying notes to tqe Consolidated Financial Results (All amounts int millions) For six months ended 30 September 2026 30 September 2025 Unaudited Unaudited 3,001 2,852 905 450 118 59 (135) (235) (236) (187) . (3) (0) (1) 4 (I) (6) (I) 129 115 (244) (4) 3,536 3,044 (1,625) (20) 48 192 (733) (352) • 145 152 1,371 3,016 (1 ,504) (988) (133) 2,028 (251) (157) 21 286 (663) . . (5,519) (12,833) (20,516) 14,015 25,817 (1 ,170) (1,968) 261 2,089 (620) 32 9 28 A (1) (260) (183) (542) (480) (793) (636) (1,546) 1,424 3,008 2,410 (48) (151) 1,414 3,683 As at 30 Seotember 2026 30 Seotember 2025 Unaudited Unaudited 866 3,683 548 . 1,414 3,683 1,-
Page 9
INDEGENE LIMITED CIN No. L 73100KA1998PLC102040 Notes to the Statement of Consolidated Financial Results for the quarter and sis. months ended 30 September 2026 (All amounts in { millions, except share data and where otherwise stated) 1. The above Consolidated Financial Results of Indegene Limited ('the Company' or 'the Parent' or 'the Holding Company' ) together with its affiliates (collectively 'the Group' ), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 • Interim Financial Reporting, recognition and measurement principles of Indian Acoounting Standards ("Ind AS") prescnbed under Section 133 of the Companies Act. 2013, as amended, read with the relevant rules issued thereunder and in tcnns of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (''the Regulations"). Due to rounding off: the numbers presented throughout may not add up precisely to the totals,. "" " in the financial infonnation denote amounts less than { 0.50 million. 2. The above Consolidated Financia1 Results have been reviewed by the Audit Committee in the meeting held on 28 October 2026 and approved by the Board of Directors at its meeting held on 29 October 2026. The statutory auditors have performed a limited review of the Consolidated Financial Results for the quarter and six months ended 30 September 2026 and have issued an unmodified review report on the same. 3. The Consolidated Financial Results for the quarter and six months ended 30 September 2026, are available on the National Stock Exchange of India Limited (URL : www .nseindia.c.om), the BSE Limited website (URL: www .bseindia.com) and on the Companys website (URL: www .indegene.com{mvestor-relations). 4. Acquisition of Cake Kommunikations On 10 November 2025, the Group had entered into a stock purchase ag:rcc:ment to acquire Cake Kommunikations Holdings GmbH (an SPV created to hold 70% in Cake Komrnunikations GmbH (Al) , 100% in CAKE Kommunikations GmbH (DE) and 100% in CAKE Kommunikations AG (Switzerland)) and 30% in Cake Kommunikations GmbH (AT) from Werner Hinterbcrger [Collectively ' Cake Group'] for an aggregate purchase consideration off 873 (EUR 8.09 million), including deferred and oontingentoonsideration . Further on 30 January 2026, the Group had obtained control of Cake Group. The Cake Group is an advertising agency specialized in hea1thcarc and pharmaceutical communication.,. The acquisition was consummated at a consideration of, 873 which includes earnout component off 383 (EUR 3.55 million) and an unconditional management incentive of, 15 (EUR 0.14 million). The earnout component is based on the perfonnance of Cake during the period commencing on l April 2025 till 31 March 2028 with the range of earnout from Nil to f 470 (EUR 4.35 million), while the unoonditional management incentive on· 15 (EUR 0.14 million) falls due on I June 2028. The Group believes that the acquisition will enable the Group to expand its healthcare marketing and communication capabilities in Europe, specifi~ally targeting the DACH region (Germany, Austria and Switzerland), thereby strengthening the Group's footprint by offering specialized, high-touch marketing services. The Group concluded that the acquired set was a business and did the provisional PPA during the year ended 31 March 2026. The same has been finalised during the period ended 30 September 2026. The following table presents the allocation of purchase price based on final PPA: Particulars A11et1 Net assets taken over [IJ Identifiable intangibles anetl Customer-rclationshi Total identifiable intangible u1ets acquired (DJ Total[l+IIJ Goodwill Total urcha1e rice Acquiree'1 carryinc amount 125 Fair value Purcbuc price adjU1tmeots allocated 283 125 283 283 408 465 873 The f.air value of net assets acquired including the identified intangibles as on the acquisition date as a part of the transaction amounted to f 408. The excess of purchase consideration over the f.air vaJue of net assets acquired has been attributed towards goodwill. The goodwill off 465 comprises value of acquired workforce and expected synergies arising from the acquisition. Net assets acquired included f 4, { 107, { 111, { 24, { 8, { 7, { 71 and f 5 I of Fixed Assets, Cash and cash equivalents, trade receivable, unbilled revenue, other assets, accounts payable, other liabilities and borrowings respectively. None of the trade receivables have been impaired and it is expected that its full contractual amount can be collected. Goodwill is allocated to Enterprise Commercial Solutions segment and is not deductible for inoome tax purposes of respective oountry tax laws. The aggregate cost incurred for the acquisition is f 53. 5. During the period ended 30 September 2026, lndegene Healthcare Gennany GmbH and Trilogy Writing & Consulting GmbH, wholly owned subsidiaries oflndegene Ireland Limited and the step-down subsidiaries of the Company entered into a merger agreement dated 22 July 2026, pursuant to which Indegene Hea1thcarc Germany GmbH was merged into Trilogy Writing &. Consulting GmbH effective 0 1 April 2026. The merger was done by way of a statutory merger by absorption under German laws, under which all assets, liabilities, rights and obligations of lndegcne Healthcare Germany GmbH were transferred to Trilogy Writing &. Consulting GmbH, and the transferor entity ceased to exist upon completion of the merger . Following the merger, Trilogy Writing &. Consulting GmbH was renamed as Indegene Heahhcare Genn.any GmbH . 6. Segment information During the year ended 31 March 2026, the Group, effective O 1 October 2025, has reorganised its segments by merging Brand Activation Segment as part of Enterprise Commercial Solutions in line with the manner in which the chief operating decision maker reviews and evaluates perfonnance of the business of the Group. Pursuant to the above, in accordance with the requirement specified in Ind AS 108, the comparative period information has been recastcd to give the effect of this change. As a oonsequence , the Group currently has 2 reportable segment i.e., Enterprise Commercial Solutions and Enterprise Medical Solutions. Se1m1ent wise revenue and results arc as follows· Quarter ended Sis: months ended Particulars 30 Seotember 30 June 30 Sent ember 30 Seotem her 30 Seotember 2026 2026 2025 2026 2025 Unaudited Unaudited Unaudited Unaudited Unaudited 1. Secment revenue Enterprise Medical Solutions 2,753 2,736 2,242 5,489 4,374 Enterprise Commercial Solutions 8,002 7,502 5,512 15,504 10,723 Othen• 468 393 288 861 553 Total • 11 223 10 631 8 042 21,854 15 650 2. ScEffi.ent results Enterprise Medical Solutions 626 716 575 1,342 1;151 Enterprise Commercial Solutions 1,302 1,197 982 2,499 2,081 Others• 3 (115 (59) (112) (109) Total 1931 1798 1498 3 729 3123 Unallocable expenses (74) (56) (92) (130) (164) Depreciation and amortisation expense (464) (441) (234) (905) (450) Other income (net) 150 290 197 440 418 Finance cost (69) (64) (38) (133) (75) Exceptional item - Tax expense (351) (365 (310) (716) (667) Profit after Tu 1123 1162 1021 2 285 2185 ~_.,~~ of consultancy and chmcal business. Year ended 31 March 2026 Audited 9,298 24,605 I 202 35105 2,435 4,492 (327) 6600 (410) (1,264) 720 (193) (203) (I 239) 4 011
Page 10
INDEGENE LIMITED CIN No. L73100KA1998PLC102040 Notes to the Statement of Consolidated Financial Results for the quarter and six months ended 30 September 2026 (All amounts in ( millions, except share data and where otherwise stated) Notes on Segment information Operating segments are identified as components of an enterprise for which discrete financials information is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and assessing perfonnance . The Group's chief ope~g decision maker is the Chief Executive Officer and Executive Director. Assets and liabilities used in the Group's business are not identified to any of the operating segments, as these are used interchangeably between segments. Management believes that it is currently not practicable to provide segment disclosures relating to total assets and liabilities since a meaningful segregation of the available data is onefous. 7. Ei.ception Item: Litia:ation E:1:penses During the financial year 2020-21, Indegene Inc. (a subsidiary of the Company) was named in a class action lawsuit filed in the U.S. District Court of New Jersey, alleging non compliance with the Telephone Consumer Protection Act of 1991 ('TCPA ') by sending unsolicited fax advertisements without the recipient's prior express invitation or pennission . Plaintiff initiated this matter through the filing of its Class Action Complaint against lndegene, Inc., lndegene Encima Inc., lndegene Wincere Inc., and lndegene Healthcare, LLC (collectively, "Indegene" or "Defendants'') seeking the Court to award actual monetary loss from the alleged TCPA violations in an amount to be proven in Court or the swn of USD 500 for each violation, whichever is greater, and that the Court award treble damages of USD 1,500 if the violations are deemed wilful or knowing. Additionally, the Plaintiff seeks the Court award pre-judgment interest and costs, to be determined upon presentation of suitable eviderrtiary support. During the year ended 31 March 2026, the matter progressed to mediation and the Group agreed in principle to a mediator-proposed settlement framework under which the Defendants would make available a maximum settlement fund of approximately t417 (USD 4.72 million), calculated at USD 250 per eligible claim. The settlement is structured as a claims-made arrangement, whereby the actual outflow is contingent upon valid claims submitted by eligible class members, and unclaimed amounts, if any, revert to the Group in accordance with the settlement terms. Accordingly, the maximum settlement fund does not represent the expected cash outflow. Based on the status of the proceedings and the Group's assessment, supported by external legal advice, the Group concluded that a present obligation existed and that an outflow of economic resources was probable and can be reliably estimated. Accordingly, the Group recognised a provision of ~03 (USD 2.30 million), including estimated legal costs, representing its best estimate of the expenditure required to settle the obligation which has been disclosed as exceptional item in the results for the year ended 31 March 2026. During the period ended 30 September 2026, pursuant to the courts orders the class administrator has issued notices to class members on 10 September 2026 requesting to submit claim forms or opt out of the settlement wherein the Class members have until 09 December 2026 to submit the claims or opt out. The Settlement payments are expected to become payable following the final fairness hearing and Court approval, in acc.ordance with the settlement terms. The amount payable will depend on valid claims submitted and attorneys' fees awarded by the Court to the Plaintiff's counsel. 1be ultimate outflow will be subject to the claims process and final Court approval. Accordingly the Group does not estimate any change in amount of provision as at 30 September 2026. 8. The shareholders approved a final dividend of ,2.25 per equity share for the financia1 year ended 31 March 2026 at the 28th Annual General Meeting held on 13 August 2026. The dividend was paid on 21 August 2026, resulting in a cash outflow of,542 million. Princeton , New Jersey 29 October 2026
Page 11
Chartered Accountants Prestige Trade Tower, Level 19 46, Palace Road, High Grounds, Bengaluru – 560 001 Karnataka, India Tel: +91 (80) 6188 6000 Fax: +91 (80) 6188 6011 IND EPENDENT AUDITOR’S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF INDEGENE LIMITED 1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of INDEGENE LIMITED (“the Company”), for the quarter and six months ended September 30, 2026 (“the Statement”) at tached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Lis ting Obligations and Disclosure Re quirements) Regulations, 2015, as amended (“the Listing Regulations”). 2. This Statement, which is the responsibility of the Company’s Management and approved by the Company’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Sec tion 133 of the Companies Act, 2013 read with re levant rules issued thereunder and other accounting pr inciples generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our respon sibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 ‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’, issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company’s personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statemen t, prepared in accordance with the recognition and me asurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclo sed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as a mended, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Deloitte Haskins & Sells Chartered Accountants Firm’s Registration No. 008072S Sathya P Koushik Partner Membership No.: 206920 UDIN: 26206920HSZFXT1201 Place: Bengaluru Date: October 29, 2026
Page 12
lndegene Limited CIN No. L 73100KA1998PLC102040 Statement of Standalone Financial Results for the quarter and six months ended 30 September 2026 SI.No. I 2 3 4 5 6 7 8 9 10 Particulan Income (a) Revenue from operations (b) Other income (net) Total income Expenses (a) Employee benefits expense (b) Finance costs ( c) Depreciation and amortisation expense ( d) Other expenses Total expenses Profit before tax (1-2) Tax expense - Current tax - Deferred tax Total tax expense Profit for the period/year (3-4) Other Comprehensive Income (OCI), net of taxes Items that will not be reclassified subsequently to the statement of pro fa or loss: Remeasurement of defined benefit obligation Deferred tax relating to items that will not be reclassified to profit and loss Items that will be reclassified subsequently to profll or loss: Net change in fair value of forward contracts designated as cash flow hedges Deferred tax relating to items that will be classified to profit and loss Total Other Comprehensive (Loss)/Income for the period/year (net of tax) Total comprehensive income for the period/year (5+6) Paid-up equity share capital (Face value on 2 each) Other eauitv Earning per equity share (face value f 2 each)• (a) Basic (int) (b) Diluted (in t) *Earnings per share IS not annual1Sed for quarter and six months ended. See accompanying notes to th~ Standalone Financial Results 30 September 2026 Unaudited 3,685 230 3,915 2,348 34 131 619 3,132 783 211 (10) 201 582 52 (13) (69) 17 (13) 569 481 2.42 2.40 ( All amounts in t millions, exceot share data and where otherwise stated) Ouarter ended Six months ended Year ended 30 June 30 September 30 September 30 September 31 March 2026 2025 2026 2025 2026 Unaudited Unaudited Unaudited Unaudited Audited 3,407 3,067 7,092 5,623 12,206 339 175 569 496 783 3,746 3,242 7,661 6,119 12,989 2,217 1,983 4,565 3,799 7,952 27 20 61 37 87 114 86 245 159 363 588 378 1,207 751 1,773 2,946 2,467 6,078 4,746 10,175 800 775 1,583 1,373 2,814 178 174 389 319 707 23 2 13 4 (12) 201 176 402 323 695 599 599 1,181 1,050 2,119 (29) 25 23 37 41 7 (7) (6) (10) (10) 40 (29) - (79) (10) - 7 - 20 8 18 (5) 27 (28) 607 617 1,176 1,077 2,091 481 480 481 480 481 20 324 2.49 2.50 4.91 4.38 8.83 2.48 2.48 4.88 4.35 8.78
Page 13
lndegene Limited CIN No. L73100KA1998PLC102040 Statement of Standalone Assets and Liabilities (All amounts in ~ millions, except share data and where otherwise stated) Particulars As at Asat 30 Seotem her 2026 31 March 2026 Unaudited Audited A ASSETS I Non-current assets (a) Property, plant and equipment 662 453 (b) Capital work-in-progress - 118 ( c) Right-of-use assets 841 673 ( d) Financial assets (i) Investments 6,166 6,166 (ii) Loan 3,169 3,550 (iii) Other financial assets 150 693 ( e) Deferred tax assets (net) 226 238 (f) Non-current tax assets (net) 37 172 (g) Other non-current assets 9 7 Total non-current assets 11,260 12,070 II Current assets (a) Financial assets (i) Investments 7,387 7,016 (ii) Loan 453 443 (iii) Trade receivables Billed 2,527 2,834 Unbilled 50 50 (iv) Cash and cash equivalents 129 485 ( v) Other bank balances 955 811 (vi) Other financial assets 1,665 291 (b) Other current assets 923 819 Total current assets 14,089 12 749 Total assets 25,349 24 819 B EQUITY AND LIABILITIES 1 Equity (a) Equity share capital 481 481 (b) Other equity 21,094 20,324 Total equity 21,575 20,805 2 Liabilities I Non-current liabilities (a) Financial liabilities (i) Lease liabilities 645 480 (ii) Other financial liabilities 31 139 (b) Provisions 692 657 Total non-current liabilities 1,368 1,276 II Current liabilities (a) Financial liabilities (i) Lease liabilities 221 218 Net decrease in cash and cash equivalents (A+B+C) ,_ Total outstanding dues of micro enterprises and small enterprises and J: 54 26 '"'j Total outstanding dues of creditors other than micro enterprises and small enterprises 332 300 (iii) Other financial liabilities 914 1,078 (b) Other current liabilities 226 272 (c) Provisions 558 534 (d) Current tax liabilities (net) 101 310 Total current liabilities 2 406 2 738 Total liabilities 3 774 4 014 Total equitv and liabilities 25349 24 819
Page 14
lndegene Limited CIN No. L73100KA1998PLC102040 Statement of Standalone Cash Flow Particulars A. Cash flows from operating activities Profit before tax for the period Adjustments to reconcile profit for the period to net cash generated from operating activities: Depreciation and amortization expense Finance costs Interest income Net gain on disposal / fair valuation of investments Gain on termination oflease Expected credit loss provision on trade receivables and advances Equity settled share based payment expenses Reversals of provision for diminution in value ofloans and interest Effect of exchange gain on restatement Operating profit before working capital changes Movements in working capital: (Increase)/decrease in trade receivables (Increase )/decrease in loans and advances and other assets Increase/ (decrease) in liabilities Increase in provisions Cash generated from operating activities Income tax paid (net) Net cash generated from operating activities (A) B. Cash flows from investing activities Purchase of property, plant and equipment Interest received Proceeds from repayments ofrelated party loan Purchase oflnvestments accounted for using the FVTPL Redemption of Investments Investment in fixed deposit Redemption / maturity of fixed deposit Net cash generated/(used) in investing activities (B) C. Cash flows from financing activities Proceeds from fresh issue of equity shares (net of share issue expense) Dividend paid Payment oflease liabilities Net cash used in financing a,ctivities (C) Net decrease in cash and cash equivalents (A+B+C) Cash and cash equivalents at the beginning of the year Effect of exchange differences on translation of foreign currency cash and cash equivalents Cash and cash equivalents at the end of the vear For the purpose of the statement of cash flows, cash and cash equivalents comprise the following : Particulars ' Balances with bank: - In current accounts - In deposit accounts Total (All amounts in ~ millions, except share data and where otherwise stated) Six months ended 30 September 2026 30 September 2025 Unaudited Unaudited 1,583 1,373 245 159 57 35 (245) (226) (236) (187) - (3) A (4) 32 47 (3) (3) (274) (67) . 1,159 1,124 262 (507) (10) 72 4 (281) 56 73 1,471 481 (463' (302) 1,008 179 (205) (169) 211 292 405 412 (1 ,600) (1,435) 1,465 1,120 (1,165) (1,965) 210 2,089 (679) 344 9 30 (542) (480) (138) (87) (671) (537) (342) (14) 485 352 (14) 15 129 353 As at ' As at 30 September 2026 ',{ 30 September 2025 ,, ; 129 353 - - 129 353
Page 15
lndegene Limited CIN No. L73100KA1998PLC102040 Notes to the Statement of Standalone Financial Results for quarter and six months ended 30 September 2026 (All amounts in t millions, except share data and where otherwise stated) I. The above Standalone Financial Results of the Indegene Limited ('the Company'), have been prepared in accordance with Indian Accounting Standards ("Ind AS") 34 - Interim Financial Reporting, recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued there under and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("the Regulations"). Due to rounding off, the numbers presented throughout may not add up precisely to the totals. """ in the financial information denote amounts less than t 0.50 million. 2. The above Standalone Financial Results have been reviewed by the Audit Committee held on 28 October 2026 and approved by the Board of Directors at its meeting held on 29 October 2026. The statutory auditors have performed a limited review of the Standalone Financial Results for the quarter and six months ended 30 September 2026 and have issued an unmodified review report on the same. 3. The Standalone Financial Results for the quarter and six months ended 30 September 2026, are available on the National Stock Exchange of India Limited (URL: www.nseindia.com), the BSE Limited website (URL: www.bseindia.com) and on the Company's website (URL: www.indegene.com/investor-relations). 4 The Company publishes this Standalone Financial Results along with the Consolidated Financial Results. In accordance with Ind AS 108, Operating Segments, the Company has disclosed the segment information in the Consolidated Financial Results. 5 The shareholders approved a final dividend of t2.25 per equity share for the financial year ended 31 March 2026 at the 28th Annual General Meeting held on 13 August 2026. The dividend was paid on 21 August 2026, resulting in a cash outflow oH542 million. Princeton, New Jersey 29 October 2026 By Order of the Board of INDEGENE LIMITED M ish Gupta Chief Executive Officer and Executive Director
Page 17
Indegene Limited Third Floor, Aspen G-4 Block, Manyata Embassy Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru- 560 045, Karnataka, India Phone: +91 80 4674 4567, +91 80 4644 7777 compliance.officer@indegene.com www.indegene.com CIN: L73100KA1998PLC102040 ANNEXURE – B Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Sl. No Particulars Details 1. Type of securities proposed to be issued Equity shares having face value of INR 2/- each 2. Type of allotment ESOP Allotment 3. Total number of securities allotted 50,009 (Fifty Thousand and Nine ) shares allotted under RSU Scheme 2020 1,429 (One Thousand Four Hundred and Twenty-Nine) shares allotted under ESOP 2020 plan without bonus element 756 (Seven Hundred and Fifty-Six) shares Allotted under ESOP 2020 plan with bonus element
Page 18
M ark F. Dzialga c/o Brighton Park Capital Management, L.P. 330 Railroad Ave., Suite 200 Greenwich, CT 06830 October 14, 2026 To: The Board of Directors Indegene Limited 3rd Floor, Aspen G-4 Block Outer Ring Road, Manyata Tech Park Nagawara, Bengaluru, Karnataka 560045, India Re: Resignation from Board of Directors Dear Members of the Board, I am writing to tender my resignation from the Board of Di rectors of Indegene Limited (the “Company”), effective October 29, 2026. This resignation follows the sale of the entire shareholding in the Company held by Brighton Park Capital and its affiliated investment vehicles, and is not on account of any disagreement with the Company on any matter relating to its operations, standards of corporate governance, or otherwise. I request the Board to take note of this resignation and to take necessary steps to intimate the same to BSE Limited and National Stock Exchange of India Limited, and to the Re gistrar of Companies, and to make the requisite filings as required under the Companies Act, 2013, and the SE BI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Yours sincerely, _____________________________ Mark F. Dzialga ANNEXURE-C
Page 19
2 ANNEXURE – D REVISED COMPOSITION OF COMMITTEES OF BOARD OF DIRECTORS (effective from 29th October 2026) NOMINATION AND REMUNERATION COMMITTEE Name Position on the Committee Designation Mr. Krishnamurthy Venugopala Tenneti Chairperson Non-Executive Independent Director Mr. Pravin Udhyavara Bhadya Rao Member Non-Executive Independent Director Mr. Jairaj Manohar Purandare Member Non-Executive Independent Director Dr. Ashish Gupta Member Non-Executive Independent Director Mr. Neeraj Bharadwaj Member Non-Executive Independent Director INVESTMENT COMMITTEE Name Position on the Committee Designation Mr. Krishnamurthy Venugopala Tenneti Chairperson Non-Executive Independent Director Dr. Ashish Gupta Member Non-Executive Independent Director Mr. Neeraj Bharadwaj Member Non-Executive Independent Director Dr. Rajesh Bhaskaran Nair Member Non-Executive Director Ms. Jill Mary De Simone Member Non-Executive Independent Director
Page 20
ANNEXURE - E
Page 21
3 ANNEXURE – F Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. Sl. No Particulars Details 1. Name of the Key Managerial Personnel Ms. Srishti Ramesh Kaushik (M. No.: A21609) 2. Reason for change viz. appointment, resignation, removal, death or otherwise Resignation from the position of Company Secretary, Compliance Officer and Key Managerial Personnel (KMP) of the Company 3. Date of appointment/cessation (as applicable) & term of appointment With effect from closure of business hours on December 02, 2026 4. Brief profile (in case of appointment) Not Applicable 5. Disclosure of relationships between directors (in case of appointment of a director) Not Applicable 6. Confirmation that there are no other material reasons other than those provided Ms. Srishti Ramesh Kaushik has confirmed that there are no material reasons for h er resignation other than those mentioned in the resignation letter dated October 29, 2026.